Two Secondary Primary Malignancies after Bortezomib Therapy for Multiple Myeloma： A Single-center Experience

Multiple myelorna （MM） is the second most common hematological malignancy. The introduction of novel agents such as thalidomide, bortezomib, and lenalidomide in more recent years has significantly improved the response rate, progression-free survival （PFS）, and overall survival （OS） of MM patients,...

Full description

Saved in:
Bibliographic Details
Published inChinese medical journal Vol. 130; no. 2; pp. 239 - 241
Main Authors Guo, Tian-Jiao, Huang, Xiao-Jun, Wen, Lei, Lu, Jin
Format Journal Article
LanguageEnglish
Published China Wolters Kluwer India Pvt. Ltd 20.01.2017
Medknow Publications and Media Pvt. Ltd
Lippincott Williams & Wilkins Ovid Technologies
Department of Hematology, Fu Xing Hospital, Capital Medical University, Beijing 100038, China%Department of Hematology, Peking University People's Hospital and Peking University Institute of Hematology, Beijing 100044, China
Department of Hematology, Peking University People's Hospital and Peking University Institute of Hematology, Beijing 100044, China
Medknow Publications & Media Pvt Ltd
Wolters Kluwer
Subjects
Aged
Analysis
Antineoplastic Agents - therapeutic use
Autografts
Bone marrow
Bortezomib
Bortezomib - therapeutic use
Bortezomib; Multiple Myeloma; Secondary Primary Malignancies
Cancer therapies
Chemotherapy
Clinical Practice
Cytogenetics
Family medical history
Female
Gene expression
Health aspects
Hematology
Hospitals
Humans
Leukemia
Male
Medical prognosis
Middle Aged
Multiple myeloma
Multiple Myeloma - drug therapy
Mutation
Patients
Stem cells
Targeted cancer therapy
Treatment outcome
Tumors
原发性
多发性骨髓瘤
恶性肿瘤
沙利度胺
治疗
硼
继发
血液系统
Secondary Primary Malignancies
Bortezomib
Multiple Myeloma
Online AccessGet full text

Cover

More Information
Summary:Multiple myelorna （MM） is the second most common hematological malignancy. The introduction of novel agents such as thalidomide, bortezomib, and lenalidomide in more recent years has significantly improved the response rate, progression-free survival （PFS）, and overall survival （OS） of MM patients, However, alongside these benefits, a significant increased risk of developing secondary primary malignancies （SPMs） has been observed. Until now, there has not been a relevant large study of Chinese MM patients available to study SPMs, and no secondary malignancy after bortezomib treatment alone has been reported.
Bibliography:Multiple myelorna （MM） is the second most common hematological malignancy. The introduction of novel agents such as thalidomide, bortezomib, and lenalidomide in more recent years has significantly improved the response rate, progression-free survival （PFS）, and overall survival （OS） of MM patients, However, alongside these benefits, a significant increased risk of developing secondary primary malignancies （SPMs） has been observed. Until now, there has not been a relevant large study of Chinese MM patients available to study SPMs, and no secondary malignancy after bortezomib treatment alone has been reported.
Bortezomib： Multiple Myeloma; Secondary Primary Malignancies
11-2154/R
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0366-6999
2542-5641
DOI:10.4103/0366-6999.198017